<DOC>
	<DOCNO>NCT01363466</DOCNO>
	<brief_summary>GYNECO 02 hypothesis hysterectomy reduce possibility local loco-regional relapse , especially patient reduce metastatic risk receive local chemoradiation therapy increase radiotherapy dos ( 45 gray ) .</brief_summary>
	<brief_title>Evaluation Hysterectomy After Chemoradiation Therapy Stage IB2/II Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<criteria>operable Stage IB2/II Cervical Cancer adenocarcinoma , squamous cell adenosquamous carcinoma Patient 18 70 year old No lomboaortic lymph node invasion baseline Previous 45 gray external pelvic radiation concomitant chemotherapy ( cisplatin 40 mg/m2/week correspond 5 cycle ) Followed 15 gray uterovaginal brachytherapy , eventually combine 6th cycle chemotherapy ( cisplatin 40 mg/m2 ) pelvic boost lymph node parametrial invasion No macroscopic residual tumor 6 8 week brachytherapy . Other tumor histology ( neuroendocrine ) Stage &gt; II ( FIGO 1995 ) baseline Patient remain cervical cancer ( subtotal hysterectomy )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>